Bausch Health Companies Inc
Most Recent
Teva Pharmaceutical: Earnings Trends and Recent Developments
Teva Pharmaceutical’s net income and diluted EPS in the first nine months of 2018 amounted to $541.0 million and $0.53, respectively.
A Financial Overview of Bausch Health in October
Bausch Health’s (BHC) net revenues declined from $4.3 billion in H1 2017 to $4.1 billion in H1 2018, reflecting an ~5.0% year-over-year decline.
Bausch Health Raises Guidance, Shares Follow
Today, Bausch Health reported its second-quarter earnings results before the market opened. It reported revenue of $2.15 billion in the quarter.
Is Bausch Health Becoming a Successful Turnaround Story?
Bausch Health (BHC) has gained 20.13% in the last month and is up by 38.93% in 2019 on a YTD basis.
BHC’s Salix Segment: Xifaxan Drove Its Revenues in Q1
In the first quarter, Bausch Health Companies (BHC) reported revenues of $445 million for its Salix segment.
What’s BHC’s Major Revenue Driver in Fiscal 2019?
In the first quarter, the Bausch + Lomb/International segment reported revenues of $1.12 billion—a rise of 1% YoY on a reported basis.
Bausch Health Companies’ Cash Flow Guidance in Fiscal 2019
Bausch Health Companies (BHC) has guided for CFO (cash flow from operations) of $1.5 billion–$1.6 billion for fiscal 2019.
Bausch Health Companies Reiterated Its Expense Guidance
Bausch Health Companies reiterated its adjusted SG&A expense guidance of $2.45 billion and R&D expense guidance of $455 million for fiscal 2019.
Bausch Health Companies Raised Its Earnings Guidance
Bausch Health Companies (BHC) raised its fiscal 2019 adjusted EBITDA guidance from $3.35 billion–$3.50 billion to $3.40 billion–$3.55 billion.
BHC: Higher Revenue Guidance for Fiscal 2019
Bausch Health Companies raised its fiscal 2019 revenue guidance from $8.30 billion–$8.50 billion to $8.35 billion–$8.55 billion.
BHC: Analysts’ Recommendations after Q1 Results
On May 6, Bausch Health Companies (BHC) reported its first-quarter results. The company reported revenues of $2.02 billion in the first quarter.
Bill Ackman Is Making a Strong Comeback in 2019
A large part of Pershing Square’s outperformance year-to-date has come from Chipotle Mexican Grill.
Analysts Reduce Target Price for Bausch Health Companies in March
Wall Street analysts expect an upside potential of 24.28% for Bausch Health Companies (BHC) based on the company’s closing price on March 22.
BHC or TEVA: Who Is Expected to Report Faster EPS Growth?
In its fourth-quarter earnings conference call, Bausch Health Companies (BHC) has guided for fiscal 2019 non-GAAP adjusted EBITDA of $3.35 billion to $3.50 billion.
BHC or Teva: Who Is Expected to Report Faster Revenue Growth?
In its fourth-quarter earnings conference call, Bausch Health Companies ( BHC) guided for fiscal 2019 revenues in the range of $8.30 billion to $8.50 billion, which implies a YoY organic growth of 0% to 3%.
What Analysts Are Recommending for Bausch Health and Teva
Since its fourth-quarter earnings release on February 20, Bausch Health Companies stock has fallen 8.06%.
What Are Bausch Health’s Key Growth Drivers in 2019?
In its fourth-quarter earnings conference call, Bausch Health Companies (BHC) has highlighted its Bausch + Lomb/International segment and Salix segment as the key growth drivers for the company in fiscal 2018.
BHC and Teva: How Tax Rate, Interest Expenses, and Capex Stack Up
In its fourth-quarter earnings investor presentation, Bausch Health Companies (BHC) has guided for a non-GAAP adjusted tax rate of 10% for fiscal 2019.
BHC and Teva: How Free Cash Flow and Net Debt Stack Up
Bausch Health Companies (BHC) and Teva Pharmaceutical (TEVA) reported free cash flow of $1.27 billion and $1.79 billion, respectively, in fiscal 2018.
BHC or Teva: Who Is Controlling Expenses Better?
In its fourth-quarter earnings investor presentation, Bausch Health Companies (BHC) guided for adjusted non-GAAP SG&A (selling, general, and administrative) expenses of $2.45 billion.
How Is Ackman Redeeming Himself after Herbalife and Valent?
Pershing Square had a series of disappointing years, with losses of 20.5%, 13.5%, 4%, and 0.7%, respectively, in 2015, 2016, 2017, and 2018.
What Are Bausch Health’s Core Growth Drivers for Next Five Years?
Bausch Health (BHC) has categorized seven of its most promising assets, which involve both recently launched and commercialized products as well as late-stage pipeline products.
Bausch Health: Strong Cash Flow Trends in Fiscal 2018
Bausch Health (BHC) generated cash from operations of $522 million in the third quarter, a YoY rise of 6.53%.
Bausch Health’s Debt Reduction Strategy
Bausch Health (BHC) reported less than $25 billion total debt on its balance sheet as of November 6, almost $7.4 billion lower than that reported by the company in the first quarter of 2016.
A Financial Overview of Teva Pharmaceutical in December
In the first nine months of 2018, Teva Pharmaceutical’s net revenue fell 16% YoY (year-over-year) to $14.3 billion from $17.0 billion.
Teva Pharmaceutical Stock Rose More than ~8% on December 26
On December 26, Teva Pharmaceutical (TEVA) stock closed at $15.82, a rise of ~8.43% from its close of $14.59 on December 24.
Bausch’s Ultra Multifocal Contact Lenses Get FDA Approval
On December 5, Bausch + Lomb announced that the FDA approved its Ultra multifocal contact lenses for patients with astigmatism.
Why Has AstraZeneca’s Stock Price Increased in 2018?
On November 19, AstraZeneca’s (AZN) stock price closed at $40.80, which represents ~5% growth from its closing price of $38.78 on October 31.
How Bausch Health’s Diversified Products Segment Has Performed
Bausch Health’s (BHC) Diversified segment consists of neurology, generics, dentistry, and other drugs.
How Is Salix Pharmaceuticals Positioned in November?
Bausch Health’s (BHC) wholly owned subsidiary Salix Pharmaceuticals generated revenues of $460.0 million in the third quarter compared to $452.0 million in the third quarter of 2017.
How Bausch Health’s Financials Look in November
Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017.
Update on Salix Pharmaceuticals’ Revenues and Developments
Salix Pharmaceutical’s gross profit increased from $318.0 million in the second quarter of 2017 to $377.0 million in the second quarter, reflecting ~19.0% YoY growth.
A Performance Overview of Bausch’s Diversified Products Business
Bausch Health Companies’ (BHC) Diversified Products segment reported net revenue of $336 million in the second quarter.
An In-Depth Look at Ortho Dermatologics in August
Ortho Dermatologics’ Onexton and Zovirax each reported revenue of $8 million in the second quarter.
A Look at the Performance of Bausch Health’s Ortho Dermatologics
Bausch Health Companies’ (BHC) wholly-owned subsidiary Ortho Dermatologics generated revenue of $142.0 million in the second quarter.
An In-Depth Look at Bausch + Lomb and Salix Pharmaceuticals
In the second quarter, Bausch + Lomb’s Lotemax, PureVision, and Artelac generated revenues of $38 million, $32 million, and $27 million, respectively.
How Is Bausch Health’s Salix Pharmaceuticals Positioned?
Bausch Health Companies’ (BHC) wholly-owned subsidiary Salix Pharmaceuticals reported revenue of $441 million in the second quarter.
A Performance Overview of Bausch + Lomb
Bausch + Lomb, an international subsidiary of Bausch Health Companies (BHC), generated revenue of $1.21 billion in the second quarter.
A Financial Overview of Bausch Health Companies in August
Bausch Health Companies reported revenue of $2.1 billion in the second quarter, reflecting a ~5% YoY (year-over-year) fall and a ~3% YoY organic rise.
